Puma Biotechnology (NASDAQ:PBYI) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI) in a research note published on Friday, Benzinga reports. The firm currently has a $7.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com cut Puma Biotechnology from a buy rating to a hold rating in a research report on Wednesday, April 10th.

Puma Biotechnology Stock Down 4.9 %

Shares of NASDAQ PBYI opened at $4.62 on Friday. Puma Biotechnology has a 52-week low of $2.13 and a 52-week high of $7.73. The company has a quick ratio of 1.38, a current ratio of 1.46 and a debt-to-equity ratio of 1.07. The company’s 50-day simple moving average is $5.31 and its 200-day simple moving average is $4.70. The firm has a market cap of $222.87 million, a price-to-earnings ratio of 14.00, a price-to-earnings-growth ratio of 2.77 and a beta of 1.31.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.07). Puma Biotechnology had a return on equity of 35.49% and a net margin of 6.79%. The firm had revenue of $72.20 million during the quarter, compared to analyst estimates of $73.22 million. Equities analysts predict that Puma Biotechnology will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Puma Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Puma Biotechnology in the 1st quarter worth approximately $57,000. Jump Financial LLC increased its holdings in shares of Puma Biotechnology by 26.6% in the third quarter. Jump Financial LLC now owns 24,690 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 5,190 shares during the last quarter. Ritholtz Wealth Management purchased a new position in Puma Biotechnology during the fourth quarter worth approximately $66,000. Crestline Management LP lifted its position in Puma Biotechnology by 6.5% during the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 2,135 shares in the last quarter. Finally, Citigroup Inc. acquired a new position in Puma Biotechnology during the third quarter worth $262,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.